Drug Trial News

RSS

Rituximab may help patients with aPL-related clinical problems

Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal Arthritis and Rheumatism.

21 Nov 2012

UMDNJ, Proteonomix commence screening of patients with ESLD for use in UMK-121 clinical trial

PROTEONOMIX, INC., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121.

21 Nov 2012

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Alzheimer's therapeutic trials have gotten bad press lately, but it is not all gloom and doom. As evident at the 5th Clinical Trials in Alzheimer's Disease (CTAD) conference, held 29-31 October in the Principality of Monaco, scientists keep extracting new data from recent drug trials to gear up for a round of new ones that aim to tackle Alzheimer's earlier than ever before.

21 Nov 2012

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

21 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

Combination of perifosine and temsirolimus shows promise against malignant glioma

Aeterna Zentaris Inc. today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG").

20 Nov 2012

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).

19 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

Interim results from RTS,S vaccine on-going phase III trial on malaria

According to the World Health Organization (WHO), more than 250 million clinical malaria cases are attributed to Plasmodium falciparum (Pf) annually, with over 1.1 million deaths in sub-Saharan Africa alone.

17 Nov 2012

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare's Virginia G. Cancer Center Clinical Trials, a partnership with the Translational Genomics Research Institute (TGen).

17 Nov 2012

Denosumab associated with improved overall survival in NSCLC patients

It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer (NSCLC) developing bone loss.

16 Nov 2012

Positive results from POZEN’s PA8140-102 Phase 1 bioavailability study

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that the results from a Phase 1 study, PA8140-102, demonstrated that PA8140, POZEN's proprietary combination of aspirin (81 mg) and omeprazole (40 mg), had comparable bioavailability relative to the reference listed product, enteric-coated (EC) aspirin (81 mg).

16 Nov 2012

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.

15 Nov 2012

Enrollment complete in Exact Sciences DeeP-C screening trial for colorectal cancer

Exact Sciences Corp. today announced it has completed patient enrollment in its DeeP-C pivotal trial for colorectal cancer screening. The study enrolled more than 12,700 patients at sites in the United States and Canada.

15 Nov 2012

Researchers describe structure of active site core of topoisomerase II alpha anti-cancer drug target

A group of researchers at the University of California, Berkeley have for the first time described the structure of the active site core of topoisomerase II alpha, an important target for anti-cancer drugs.

15 Nov 2012

Positive preliminary results from ImmunoPulse Phase II trial in metastatic melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.

15 Nov 2012

Trastuzumab increases risk of heart failure in older women with breast cancer

Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin-), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.

15 Nov 2012

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax's single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta.

15 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Blog examines RTS,S malaria vaccine trial results

In a post in the Center for Global Development's (CGD) "Global Health Policy" blog, Owen Barder, a senior fellow and director for Europe at the CGD, reports on the results of a large Phase III clinical trial conducted in Africa on the malaria vaccine candidate RTS,S, published online in the New England Journal of Medicine on Friday.

14 Nov 2012

Drug Trial News

Rituximab may help patients with aPL-related clinical problems

UMDNJ, Proteonomix commence screening of patients with ESLD for use in UMK-121 clinical trial

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Combination of perifosine and temsirolimus shows promise against malignant glioma

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Interim results from RTS,S vaccine on-going phase III trial on malaria

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

Denosumab associated with improved overall survival in NSCLC patients

Positive results from POZEN’s PA8140-102 Phase 1 bioavailability study

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

Enrollment complete in Exact Sciences DeeP-C screening trial for colorectal cancer

Researchers describe structure of active site core of topoisomerase II alpha anti-cancer drug target

Positive preliminary results from ImmunoPulse Phase II trial in metastatic melanoma

Trastuzumab increases risk of heart failure in older women with breast cancer

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Blog examines RTS,S malaria vaccine trial results

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News